Golden
LoginSign Up
Indee Labs

Indee Labs

Indee Labs focuses on the development of microfluidic vortex shedding for rapidly and efficiently transfecting human primary immune cells with negligible perturbation. The team is focused on developing its core technology for short turnaround chimeric antigen receptor T cell (CAR-T) development and manufacturing.

All edits by  Ryan Pawell 

Edits on 7 Nov 2018
Ryan Pawell
Ryan Pawell edited on 7 Nov 2018 10:11 pm
Edits made to:
Article (+0/-0 images) (+0/-0 videos) (+3/-3 characters)

Article

As of May 2018, Indee Labs had accumulated more than USD$5.66.1 million dollars in angel, venture and non-dilutive capital.

Edits on 21 Sep 2018
Ryan Pawell
Ryan Pawell edited on 21 Sep 2018 7:56 pm
Edits made to:
People (+4/-0 cells) (+64/-0 characters)

People

Name
Role
Related Golden topics

Julyana Acevado, PhD

Scientist

Justin Jarrell, PhD

Scientist

Moein Kashani, PhD

Scientist

Ragesh Nair

Bioengineer

Warren McKenzie, PhD

CEO, Australia

Ryan Pawell"team and vortex shedding clarification"
Ryan Pawell edited on 21 Sep 2018 7:21 pm
Edits made to:
Article (+0/-0 images) (+0/-0 videos) (+169/-0 characters)
People (+14/-0 cells) (+155/-0 characters)

Article

The core technology, microfluidic vortex shedding (μVS), uses a microscopic fluid dynamics phenomenon based on vortex shedding to hydrodynamically porate the cell membrane allowing for the deliberate introduction of genetic material to human primary immune cells. Vortex shedding is not a new phenomenon. It can be observed as water flows past boulders in rivers while also being seen as clouds drift over mountains.

...

In July 2017, Indee Labs closed USD$1.3M in accelerator and angel financing from SOSV, IndieBio, Jude Gomila, Shaun Maguire, Y Combinator and Jaffray Woodriff (executed by his family office, Felton Group, LLC) among others.

People

Name
Role
Related Golden topics

Adrian Lievano

Bioengineer

Julyana Acevado

Scientist

Justin Jarrell

Scientist

Katherine Lau

Bioengineer

Ryan Pawell

CEO

Taylor Murphy

VP, Operations

Warren McKenzie

CEO, Australia

Edits on 25 Aug 2018
Ryan Pawell
Ryan Pawell edited on 25 Aug 2018 8:38 pm
Edits made to:
People (+0/-1 cells) (+0/-14 characters)

People

Name
Role
Related Golden topics

Amy Twite, PhD

Edits on 14 Aug 2018
Ryan Pawell"update total fundraise amount"
Ryan Pawell edited on 14 Aug 2018 8:36 pm
Edits made to:
Article (+3/-3 characters)

Article

As of May 2018, Indee Labs had accumulated more than USD$5.45.6 million dollars in angel, venture and non-dilutive capital.

Ryan Pawell"add MDF fund award"
Ryan Pawell edited on 14 Aug 2018 8:12 pm
Edits made to:
Article (+5/-0 cells) (+194/-0 characters)
Edits on 17 May 2018
Ryan Pawell
Ryan Pawell edited on 17 May 2018 8:43 pm
Edits made to:
Article (+16/-16 characters)

Article

In July 2017, Indee Labs closed USD$1.3M in accelerator and angel financing from Jude Gomila, Shaun Maguire, Y Combinator and Jaffray WoodriffJaffray Woodriff (executed by his family office, Felton Group, LLC) among others.

Ryan Pawell
Ryan Pawell edited on 17 May 2018 8:42 pm
Edits made to:
Article (+93/-26 characters)

Article

In July 2017, Indee Labs closed USD$1.3M in accelerator and angel financing from Jude Gomila, Shaun Maguire and, Y Combinator and Jaffray Woodriff (executed by his family office, Felton Group, LLC) among others.

...

In May 2018, Indee Labs closed out a seed round resulting in USD$2.6M in angel and venture financing from Founders FundFounders Fund, Main Sequence Ventures, Social+Capital also among others.

...
Award
Funding Agency
Value
Year
Link

BioMedTech Horizons Precision Medicine

MTP Connect

AUD$891,500

2018-20202018-20

Edits on 16 May 2018
Ryan Pawell
Ryan Pawell edited on 16 May 2018 11:06 pm
Edits made to:
Article (+2/-6 characters)

Article

Indee Labs was founded onin August 16, 2015 with a 'mission to democratize gene-modified cell therapies' such as chimeric antigen receptor T cells (CAR-T). The team is developing a novel transfection technology that can rapidly and efficiently deliver a variety of genetic material (e.g., DNA, RNA, protein and/or various complexes) to human primary immune cells in seconds.

Ryan Pawell
Ryan Pawell edited on 16 May 2018 11:03 pm
Edits made to:
Article (+20/-17 characters)

Article

Government Grants

Non-dilutive Funding

Ryan Pawell"Bringing all online material inline with funding announcements to avoid confusion during PR."
Ryan Pawell edited on 16 May 2018 7:08 pm
Edits made to:
Article (+129/-255 characters)

Article

As of AprilMay 20172018, Indee Labs had accumulated more than USD$4.45.4 million dollars in angel, venture and non-dilutive capital.

...

In FebruaryJuly 20162017, Indee Labs closed USD$550K1.3M in accelerator and angel financing from IndieBioJude Gomila, Shaun Maguire and SOSVY Combinator among others.

...

In March ofMay 20172018, Indee Labs kickedclosed offout a seed round resulting in USD$3M2.6M in angel and venture financing from JudeFounders GomilaFund, Shaun Maguire,Main YSequence CombinatorVentures, Social+Capital, Main Sequence Ventures and Founders Fundalso among others inclusive of refunds under an Overseas Finding for Australia's R&D Tax Incentive.

...
Award
Funding Agency
Value
Year
Link

Overseas Finding

AusIndustry

43.5% of eligible R&D expenditureAUD$502,050

2016-18

https://www.business.gov.au/assistance/research-and-development-tax-incentive

Edits on 21 Apr 2018
Ryan Pawell
Ryan Pawell edited on 21 Apr 2018 8:38 pm
Edits made to:
Article (+5/-5 cells) (+3/-110 characters)

Article

Award
Funding Agency
Value
Year
Link

BioMedTech Horizons

MTP Connect

AUD$891,500

2018-20

BioMedTech Horizons Precision Medicine

MTP Connect

AUAUD$891,500

2018-2020

Ryan Pawell"Add MTP Connect grant"
Ryan Pawell edited on 21 Apr 2018 8:37 pm
Edits made to:
Article (+5/-0 cells) (+128/-0 characters)

Article

Award
Funding Agency
Value
Year
Link

BioMedTech Horizons Precision Medicine

MTP Connect

AU$891,500

2018-2020

Edits on 17 Apr 2018
Ryan Pawell"grants"
Ryan Pawell edited on 17 Apr 2018 1:43 pm
Edits made to:
Article (+5/-0 cells) (+108/-0 characters)

Article

Award
Funding Agency
Value
Year
Link

BioMedTech Horizons

MTP Connect

AUD$891,500

2018-20

Edits on 5 Apr 2018
Ryan Pawell"finished timeline."
Ryan Pawell edited on 5 Apr 2018 12:53 am
Edits made to:
Article (+199/-199 characters)

Article

1 February1 February Indee Labs presents at MF-9, the Ninth Microfluidics Consortium.

24 January Indee Labs featured by Main Sequence Ventures.

...

2124 January January Indee Labs featured by #AUSinnovatesMain Sequence Ventures.

...

12 January Moein featured by ANSYS for his simulation and High Performance Computing work.

21 January Indee Labs featured by #AUSinnovates.

...

12 January Moein featured by ANSYS for his simulation and High Performance Computing work.

8 January8 January Indee Labs mentioned by the Australian Trade and Investment Commission.

...

7 December7 December Indee Labs selected for the Wilson Sonsini Goodrich & Rosati Healthcare Innovations Venture Investment Forum.

Ryan Pawell"timeline with links"
Ryan Pawell edited on 5 Apr 2018 12:51 am
Edits made to:
Article (+2395/-0 characters)

Article

Timeline

2018

1 February Indee Labs presents at MF-9, the Ninth Microfluidics Consortium.

24 January Indee Labs featured by Main Sequence Ventures.

21 January Indee Labs featured by #AUSinnovates.

12 January Moein featured by ANSYS for his simulation and High Performance Computing work.

8 January Indee Labs mentioned by the Australian Trade and Investment Commission.

2017

7 December Indee Labs selected for the Wilson Sonsini Goodrich & Rosati Healthcare Innovations Venture Investment Forum.

21 November Indee Labs presents at the Make & Measure 2017 ANFF & AMMRF Research Showcase celebrating 10 year of Australia's National Collaborative Research Infrastructure.

18 November Indee Labs featured in Australian National Fabrication Facility's 2017 Casebook celebrating 10 year of Australia's National Collaborative Research Infrastructure.

15 November Indee Labs featured by Eagar & Martin Patent & Trademark Attorneys.

4 October Amy presents a Lightning Talk at Synbiobeta.

29 September Indee Labs featured in Evolve Magazine.

20 September Indee Labs mentioned in Startup Daily News.

29 August Indee Labs mentioned by Computerworld.

25 August Indee Labs mentioned by the Australian Trade and Investment Commission.

3 July Indee Labs closes $1.3M Angel Round.

14 June Indee Labs presents at the Australian-American Emerging Cancer Technologies Meeting.

31 May Indee Labs featured in STAT News.

11 May Indee Labs featured in Slate Star Codex.

18 April Indee Labs presents at [email protected]’s Amgen Innovator Series.

20 March Indee Labs launches at Y Combinator’s Winter 2017 Demo Day.

2016

Indee Labs participates in AusTrade’s San Francisco Landing Pad prior to being selected for Y Combinator’s Winter 2017 cohort and the MBC Biolabs (née [email protected]) portfolio in San Francisco.

2 November Indee Labs presents at the Air Force Office of Scientific Research's Life Science Review.

2 November Indee Labs receives Jobs for NSW Minimum Viable Product Grant.

24 May Indee Labs selected to present at Australian-American Enabling Technologies Meeting.

22 April Indee Labs featured by Vator News.

22 January Indee Labs featured by IndieBio.

2015

12 June Indee Labs featured in Science Alert.

...

2014

Ryan has the ‘aha’ moment while studying the fluid dynamics of microfluidic post arrays at the Australian National Fabrication Facility and graduates from the NSW Health and Cicada Innovations Medical Device Commercialisation Training Program.

Ryan Pawell
Ryan Pawell edited on 5 Apr 2018 12:08 am
Edits made to:
Description (+19/-3 characters)
Topic thumbnail

Indee Labs

Indee Labs focuses on the development of microfluidic vortex shedding for rapidly and efficiently transfecting human primary immune cells with negligible perturbation. The team is focused on developing μVSits core technology for short turnaround chimeric antigen receptor T cell (CAR-T) development and manufacturing.

Ryan Pawell
Ryan Pawell edited on 5 Apr 2018 12:06 am
Edits made to:
Article (+74/-39 characters)

Article

Indee Labs was founded on August 16, 2015 with a mission to democratize ex vivogene-modified cell therapies such as chimeric antigen receptor T cells (CAR-T). The team is developing a novel transfection technology that can rapidly and efficiently deliver a variety of genetic material (e.g., DNA, RNA, protein and/or various complexes) to human primary immune cells in seconds.

...

μVS is not the only transfection technology, however, it is shown to be able to rapidly deliver a range of genetic material to human primary immune cells with high cell recovery, high cell viability and high efficiency and high throughput. Furthermore, μVS results in negligible perturbation of immune cell proliferation, activation, exhaustion, phenotype, function nor transcriptome-wide gene expression. μVS is also induced with a 5 mm x 10 mm microfluidic device manufactured using industry-standard semiconductor processes. Cumulatively, this means μVS is an extremely scalable, gentle and robust alternative to incumbent technologies such as viralviral transductiontransduction and electroporationelectroporation.

...

As of April 2017, Indee Labs had accumulated more than USD$4.4 million dollars in angel, venture and non-dilutive capital.

...

In February 2016, Indee Labs closed USD$550K in accelerator and angel financing from IndieBio and SOSV among others.

...

In March of 2017, Indee Labs kicked off a seed round resulting in USD$3M in angel and venture financing from Jude Gomila, Shaun Maguire, Y Combinator, Social+Capital, Main Sequence Ventures and Founders Fund among others inclusive of refunds under an Overseas Finding for Australia's R&D Tax Incentive.

Ryan Pawell
Ryan Pawell edited on 5 Apr 2018 12:02 am
Edits made to:
Description (+298/-349 characters)
Article (+10/-0 cells) (+1897/-0 characters)
Topic thumbnail

Indee Labs

Indee Labs is a Y Combinator startup founded in August 2015 to develop scalable hardware for gene delivery. Indee Labs is using patent-pending, microscopic fluid dynamics called microfluidic vortex shedding (µVS). µVS enables rapid, scalable and high-fidelity delivery to immune cells that is not possible with viral transduction and electroporation

Indee Labs focuses on the development of microfluidic vortex shedding for rapidly and efficiently transfecting human primary immune cells with negligible perturbation. The team is focused on developing µVS for short turnaround chimeric antigen receptor T cell (CAR-T) development and manufacturing.

Article

Indee Labs was founded on August 16, 2015 with a mission to democratize ex vivo cell therapies such as chimeric antigen receptor T cells (CAR-T). The team is developing a novel transfection technology that can rapidly and efficiently deliver a variety of genetic material (e.g., DNA, RNA, protein and/or various complexes) to human primary immune cells in seconds.

Microfluidic Vortex Shedding

The core technology, microfluidic vortex shedding (µVS), uses a microscopic fluid dynamics phenomenon based on vortex shedding to hydrodynamically porate the cell membrane allowing for the deliberate introduction of genetic material to human primary immune cells.

µVS is not the only transfection technology, however, it is shown to be able to rapidly deliver a range of genetic material to human primary immune cells with high cell recovery, high cell viability and high efficiency. Furthermore, µVS results in negligible perturbation of immune cell proliferation, activation, exhaustion, phenotype, function nor transcriptome-wide gene expression. µVS is also induced with a 5 mm x 10 mm microfluidic device manufactured using industry-standard semiconductor processes. Cumulatively, this means µVS is an extremely scalable, gentle and robust alternative to incumbent technologies such as viral transduction and electroporation.

Funding

As of April 2017, Indee Labs had accumulated more than $4.4 million dollars in angel, venture and non-dilutive capital.

Angel

In February 2016, Indee Labs closed $550K in accelerator and angel financing from IndieBio and SOSV among others.

Seed

In March of 2017, Indee Labs kicked off a seed round resulting in $3M in angel and venture financing from Jude Gomila, Shaun Maguire, Y Combinator, Social+Capital, Main Sequence Ventures and Founders Fund among others inclusive of refunds under an Overseas Finding for Australia's R&D Tax Incentive.

Government Grants

Award
Funding Agency
Value
Year
Link

Minimum Viable Product

Jobs for NSW

AUD$15,000

2016

Overseas Finding

AusIndustry

43.5% of eligible R&D expenditure

2016-18

Edits on 13 Jan 2018
Ryan Pawell"Minor Edits"
Ryan Pawell edited on 13 Jan 2018 11:16 pm
Edits made to:
Description (+26/-23 characters)
Topic thumbnail

Indee Labs

Indee Labs is a Y Combinator startup founded in August 2015 to develop scalable hardware for gene delivery. Indee Labs is using patent-pending, microscopic fluid dynamics called microfludicmicrofluidic vortex shedding (μVS). μVS enableenables rapid, scalable and high-fidelity gene delivery to immune cells that is not possible with viral transduction and electroporation.